333 related articles for article (PubMed ID: 30140882)
1. Screening for Cervical Cancer in Primary Care: A Decision Analysis for the US Preventive Services Task Force.
Kim JJ; Burger EA; Regan C; Sy S
JAMA; 2018 Aug; 320(7):706-714. PubMed ID: 30140882
[TBL] [Abstract][Full Text] [Related]
2. Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Melnikow J; Henderson JT; Burda BU; Senger CA; Durbin S; Weyrich MS
JAMA; 2018 Aug; 320(7):687-705. PubMed ID: 30140883
[TBL] [Abstract][Full Text] [Related]
3. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement.
; Curry SJ; Krist AH; Owens DK; Barry MJ; Caughey AB; Davidson KW; Doubeni CA; Epling JW; Kemper AR; Kubik M; Landefeld CS; Mangione CM; Phipps MG; Silverstein M; Simon MA; Tseng CW; Wong JB
JAMA; 2018 Aug; 320(7):674-686. PubMed ID: 30140884
[TBL] [Abstract][Full Text] [Related]
4. Estimated Quality of Life and Economic Outcomes Associated With 12 Cervical Cancer Screening Strategies: A Cost-effectiveness Analysis.
Sawaya GF; Sanstead E; Alarid-Escudero F; Smith-McCune K; Gregorich SE; Silverberg MJ; Leyden W; Huchko MJ; Kuppermann M; Kulasingam S
JAMA Intern Med; 2019 Jul; 179(7):867-878. PubMed ID: 31081851
[TBL] [Abstract][Full Text] [Related]
5. Primary cervical screening with high risk human papillomavirus testing: observational study.
Rebolj M; Rimmer J; Denton K; Tidy J; Mathews C; Ellis K; Smith J; Evans C; Giles T; Frew V; Tyler X; Sargent A; Parker J; Holbrook M; Hunt K; Tidbury P; Levine T; Smith D; Patnick J; Stubbs R; Moss S; Kitchener H
BMJ; 2019 Feb; 364():l240. PubMed ID: 30728133
[TBL] [Abstract][Full Text] [Related]
6. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
Kim JJ; Burger EA; Sy S; Campos NG
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of the 2019 American Society for Colposcopy and Cervical Pathology Risk-Based Management Consensus Guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.
Munshi VN; Perkins RB; Sy S; Kim JJ
Am J Obstet Gynecol; 2022 Feb; 226(2):228.e1-228.e9. PubMed ID: 34547295
[TBL] [Abstract][Full Text] [Related]
8. Screening for cervical cancer: a modeling study for the US Preventive Services Task Force.
Kulasingam SL; Havrilesky LJ; Ghebre R; Myers ER
J Low Genit Tract Dis; 2013 Apr; 17(2):193-202. PubMed ID: 23519288
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China: A Multicenter, Open-label, Randomized Clinical Trial.
Zhang J; Zhao Y; Dai Y; Dang L; Ma L; Yang C; Li Y; Kong L; Wei L; Zhang S; Liu J; Xi M; Chen L; Duan X; Xiao Q; Abulizi G; Zhang G; Hong Y; Gao X; Zhou Q; Xie X; Li L; Niyazi M; Zhang Z; Tuo J; Ding Y; Si M; Chen F; Song L; Qiao Y; Lang J
JAMA Oncol; 2021 Feb; 7(2):263-270. PubMed ID: 33377903
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of High-Risk Human Papillomavirus Testing With Messenger RNA Versus DNA Under United States Guidelines for Cervical Cancer Screening.
Ting J; Smith JS; Myers ER
J Low Genit Tract Dis; 2015 Oct; 19(4):333-9. PubMed ID: 26225945
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of HPV-based cervical screening based on first year results in the Netherlands: a modelling study.
Jansen E; Naber SK; Aitken CA; de Koning HJ; van Ballegooijen M; de Kok I
BJOG; 2021 Feb; 128(3):573-582. PubMed ID: 32638462
[TBL] [Abstract][Full Text] [Related]
12. High-risk HPV testing vs liquid-based cytology for cervical cancer screening among 25- to 30-year-old women: A historical cohort study.
Feldstein O; Gali-Zamir H; Schejter E; Feinberg T; Yehuda-Shnaidman E; Bornstein J; Levy T
Acta Obstet Gynecol Scand; 2023 Feb; 102(2):226-233. PubMed ID: 36478537
[TBL] [Abstract][Full Text] [Related]
13. Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.
Schiffman M; Kinney WK; Cheung LC; Gage JC; Fetterman B; Poitras NE; Lorey TS; Wentzensen N; Befano B; Schussler J; Katki HA; Castle PE
J Natl Cancer Inst; 2018 May; 110(5):501-508. PubMed ID: 29145648
[TBL] [Abstract][Full Text] [Related]
14. History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China.
Tao X; Griffith CC; Zhou X; Wang Z; Yan Y; Li Z; Zhao C
Cancer Cytopathol; 2015 Jul; 123(7):421-7. PubMed ID: 25955972
[TBL] [Abstract][Full Text] [Related]
15. Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force.
Knudsen AB; Zauber AG; Rutter CM; Naber SK; Doria-Rose VP; Pabiniak C; Johanson C; Fischer SE; Lansdorp-Vogelaar I; Kuntz KM
JAMA; 2016 Jun; 315(23):2595-609. PubMed ID: 27305518
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of p16/Ki-67 Dual-Stained Cytology Reflex Following Co-testing with hrHPV Genotyping for Cervical Cancer Screening.
Harper DM; Anderson RJ; Baker E; Yu TM
Cancer Prev Res (Phila); 2023 Jul; 16(7):393-404. PubMed ID: 37210751
[TBL] [Abstract][Full Text] [Related]
17. Modeling the Balance of Benefits and Harms of Cervical Cancer Screening with Cytology and Human Papillomavirus Testing.
Malagón T; Mayrand MH; Ogilvie G; Gotlieb WH; Blake J; Bouchard C; Franco EL; Kulasingam S
Cancer Epidemiol Biomarkers Prev; 2020 Jul; 29(7):1436-1446. PubMed ID: 32332032
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
